Patent ID: 9216170
Filing Date: 2015-12-22
Classification: A61K,A61P

Abstract:
1. A method of treating a patient suffering from a proliferative disorder, comprising administering to the patient, either concomitantly or sequentially: (i) a first component comprising, as an active agent, vemurafenib, or a pharmaceutically-acceptable salt thereof, and (ii) a second component comprising, as an active agent, an MDM2 inhibitor, or a pharmaceutically: acceptable salt thereof; the amount of said active agents being such that the combination thereof is therapeutically effective in the treatment of said proliferative disorder; wherein said proliferative disorder is a melanoma or a colorectal cancer that involves a tumor comprising b-Raf having the V600E mutation; and said MDM2 inhibitor is Compound II: or Compound III: or a pharmaceutically-acceptable salt thereof.